



Early View

Original research article

The trajectory of COVID-19 cardiopulmonary disease: insights from an autopsy study of community-based, pre-hospital deaths

Luke Milross, Joaquim Majo, Julian Pulle, Sam Hoggard, Nigel Cooper, Bethany Hunter, Christopher JA Duncan, Andrew Filby, Andrew J. Fisher

Please cite this article as: Milross L, Majo J, Pulle J, *et al.* The trajectory of COVID-19 cardiopulmonary disease: insights from an autopsy study of community-based, pre-hospital deaths. *ERJ Open Res* 2022; in press (<https://doi.org/10.1183/23120541.00303-2022>).

This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Research Article

The trajectory of COVID-19 cardiopulmonary disease: Insights from an autopsy study of community-based, pre-hospital deaths.

Luke Milross MD¹, Joaquim Majo PhD², Julian Palle MBChB², Sam Hoggard MBChB², Nigel Cooper MBBS², Bethany Hunter BSc MRes³, Christopher JA Duncan DPhil^{1,4}, Andrew Filby PhD³ and Andrew J. Fisher PhD FRCP^{1,5,*}.

¹Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK

²Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

³Innovation Methodology and Application Research Theme, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK

⁴Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

⁵Institute of Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Abstract:

Background: Post-mortem examination of lung and heart tissue has been vital to developing an understanding of COVID-19 pathophysiology, however studies to date have almost uniformly used tissue obtained from hospital-based deaths where individuals have been exposed to major medical and pharmacological interventions.

Methods: In this study we investigated patterns of lung and heart injury from 46 community-based, pre-hospital COVID-19-attributable deaths who underwent autopsy.

Results: The cohort comprised 22 females and 24 males, median age 64 years (range 19-91) at time of death with illness duration range 0-23 days. Comorbidities associated with poor outcomes in COVID-19 were represented with obesity (BMI>30kg/m²) in 19/46 cases (41.3%). Diffuse alveolar damage (DAD) in its early exudative phase was the most common pattern of lung injury, however significant heterogeneity was identified with bronchopneumonia, pulmonary oedema consistent with acute cardiac failure, pulmonary thromboembolism and microthrombosis also identified and often in overlapping patterns. Review of clinical records and next of kin accounts suggested a combination of unexpectedly low symptom burden, rapidly progressive disease and psychosocial factors may have contributed to a failure of hospital presentation prior to death.

Conclusions: Identifying such advanced acute lung injury in community-based deaths is extremely unusual and raises the question why some with severe COVID-19 pneumonitis were not hospitalised. Multiple factors that include low symptom burden, rapidly progressive disease trajectories and psychosocial factors provide possible explanations.

Keywords: COVID-19, community, post-mortem, autopsy, lung, heart, pathology.

Abstract word count: 223.

Word count: 3851.

Figure/table count: 8.

1. Introduction

Autopsies have been critical to our understanding of nascent disease pathophysiology for centuries and the COVID-19 pandemic is no exception. True to its Ancient Greek etymology, '*autopsia*' allows the pathologist to 'see for oneself' a temporal snapshot of diseased tissue at the time of death¹. Peripheral blood sampling and radiological studies have informed much of our knowledge of COVID-19 pathophysiology to date and although they are critical metrics, they provide mere inferences of the cellular responses and architectural injury hidden at the tissue level. The respiratory tract is the initial target of severe acute respiratory coronavirus 2 (SARS-CoV-2) and the most important site of disease progression². Through autopsy series, diffuse alveolar damage (DAD), referring to a pattern of injury to pneumocytes and alveolar endothelial cells³, has emerged as the dominant histological phenotype in COVID-19 post-mortem lung tissue (PMLT) obtained from the hospital setting⁴ and can be found in two distinct phases; an early or exudative phase and a later proliferative and organising phase⁴. COVID-19 PMLT from hospital-based series is also extensively heterogeneous and often features superimposed bacterial bronchopneumonia, fungal infection, pulmonary features of acute cardiac failure and thrombosis⁵⁻⁷.

The majority of published autopsy series have focused on hospital-based deaths with community-based series being scarce⁸. DAD was described in some early community-based case reports⁹⁻¹¹ and case series^{8,12-14}, however it is possible these do not cover the full clinicopathological spectrum in the community due to their small cohort numbers. Most importantly, in the pre-COVID-19 era, DAD was classically associated with the severe clinical trajectory of ARDS and significant symptom burden necessitating critical care support^{15,16}. DAD featuring in community-based autopsies has therefore bewildered pathologists and explanations for why these people died at home rather than presenting to hospital are needed. During the COVID-19 pandemic, the phenomenon of 'silent hypoxia' has been observed by clinicians, whereby severely low oxygen saturations, evidence of significant functional lung impairment, seems to be able to coexist with an incongruously low symptom burden¹⁷. In this study, we have integrated clinical, microbiological, macroscopic and histopathological data to provide a full picture of the pathological spectrum of cardiopulmonary disease in fatal COVID-19 cases in the community as well as chronicle symptomatic burden prior to death based on collateral accounts from next of kin.

2. Methods

A list was collated by the Newcastle upon Tyne NHS Foundation Trust Department of Cellular Pathology of all individuals referred for an HM Coroner's autopsy if they died in the community with proven or suspected COVID-19 before any hospital-based intervention, or if they died unexpectedly in the community and screening COVID-19 swabs were positive. Deaths included occurred between April 2020 and August 2021, corresponding to the first and second 'waves' of COVID-19 in the UK. Autopsies were performed by a consultant pathologist following published risk reduction strategies¹⁸. Swabs of the nose, throat and/or lung parenchyma were taken for SARS-CoV-2 polymerase chain reaction (PCR) testing during autopsy. Only cases with positive SARS-CoV-2 PCR results were included in the study. Clinical metadata was collected routinely at autopsy and with the aid of collateral history from next of kin and included basic demographics, BMI, symptoms prior to death, duration of illness and presence of comorbidities. Metadata was then extracted from available autopsy reports retrospectively and tabulated. Individuals were only included if it was determined that COVID-19 disease was the primary cause of death.

Macroscopic findings gathered included the significant pathological features on visual and tactile inspection and weights of the right and left lungs and the heart. Lung and heart samples were formalin fixed, paraffin-embedded, sectioned, mounted and stained for analysis. The microscopic slides were reviewed by pathologists with special expertise in cardiothoracic pathology. Their objective was to determine the dominant histological pattern of disease which, within the context of all other post-mortem findings, was most likely to have caused death. Other pathologies that were thought to have played a non-dominant yet significant role in demise were reported as secondary pathologies. Considering the clinical, macroscopic and microscopic data, individuals were then classified into phenotypic groups by disease process.

Finally, based on the themes emerging from our analysis of clinical narratives, we hypothesised that a low symptom burden may have contributed to death in the community as individuals would be less likely to seek medical attention. We collated those in the cohort who had collateral history documented within the autopsy report clearly stating that prior to death the individual was i) asymptomatic, or ii) had no lower respiratory tract (LRT) symptoms (and only had extra-pulmonary symptoms) or iii) a qualifier synonymous to 'mild' was used to describe any LRT symptoms present. All patients meeting these definitions were collated into a 'low symptom burden' group for later analysis. To illustrate further which individuals might constitute this group, it would equally include an asymptomatic individual, a person with slight shortness of breath and a person with isolated myalgia. Respiratory symptoms included shortness of breath, cough, sputum production, haemoptysis, wheeze and chest pain or tightness. Common extra-pulmonary symptoms were also collated including enteric symptoms (diarrhoea, vomiting, abdominal pain), fever and other systemic symptoms (such as myalgia, arthralgia, cutaneous exanthems).

3. Results

3.1 Cohort demographic and clinical data

Our study identified 46 individuals who died at home in North-East England in the first and second ‘waves’ of the COVID-19 pandemic without admission to hospital during their period of illness, with autopsies occurring between April 2020 and August 2021. All 46 were confirmed to be SARS-CoV-2 positive by PCR post-mortem at autopsy. Age at death ranged from 19-91 (Table 1). 19/46 (41.3%) were ≤ 60 years old. Basic demographic information including prevalence of ‘COVID-19-relevant’ comorbidities, symptoms and illness duration are summarised by Table 1.

Table 1. Cohort demographics and clinical metadata.

Characteristics (n=46)	Data (% cohort)
Age (years)	
Median	64
Range	19 - 91
Sex	
Female	22 (47.8%)
Ethnicity	
White	43 (93.5%)
BAME	3 (6.5%)
Duration of Illness (days)	
Range	0-23
Mean	5.9
Median	5
Symptoms (n=where symptoms known)	
Respiratory (n=37)	22 (59.5%)
Fever (n=37)	8 (21.6%)
Enteric (n=37)	4 (10.8%)
Systemic (n=37)	20 (54.1%)
Asymptomatic (n=37)	3 (8.1%)
Nil or ‘mild’ LRT symptoms (n=37)	17 (45.9%)
Comorbidities	
Pre-existing cardiac disease	14 (30.4%)
Hypertension	12 (26.1%)
Diabetes	8 (17.4%)
COPD/asthma	10 (21.7%)
CKD	8 (17.4%)
Significant smoking history	8 (17.4%)
Obesity	19 (41.3%)
Dementia	6 (13%)
1+ of above comorbidities	25 (54%)

3.2 Lung findings

The lungs were generally heavier than normal reference weights¹⁹ with the left lung median 754g (range 320-1306g) and 904g for the right (range 445-1604g). A median of 7 blocks/case (range: 2-11) underwent histopathological evaluation. Pulmonary oedema and congestion were reported most frequently, featuring in 41/46 cases (89.1%). Pneumonic consolidation featured in 7/46 (15.2%), focal haemorrhage in 5/46 (10.9%) and pulmonary thromboembolism of medium calibre arteries (1-10mm diameter) and large calibre arteries (>10mm) in 3/46 (6.5%). In 5/46 cases (10.9%) a chronic respiratory condition was noted, including emphysema in four cases and pulmonary fibrosis in two cases (there was one case where both conditions were present).

Based on the clinical data, macroscopic findings and microscopic evaluation, the cases were grouped into four predominant disease phenotypes: 1) DAD, 2) acute (neutrophilic) bronchopneumonia (BRON), 3) pulmonary thromboembolism (PTE) of medium and large calibre arteries and 4) pulmonary oedema due to presumed acute cardiac failure (PO-PACF) (Figure 1). Since pulmonary

oedema (PO) is a feature of the very early exudative phase of DAD, cases with PO without evidence of exudative/proliferative alveolar damage and within the context of concordant clinical and pathological findings were defined as PO-PACF.

DAD was the most frequent dominant histopathological phenotype, expressed in 26/46 cases (56.5%), with 25/26 in a predominantly exudative phase and just one case, who had had a 21-day illness duration, where the organising phase represented the dominant injury. BRON featured as a dominant phenotype in 11/46 (23.9%), PO-PACF in 7/46 (15.2%) and PTE in 2/46 (4.3%).




Figure 1: Haematoxylin and eosin-stained post-mortem lung sections – dominant pathology phenotypes

(A) DAD exudative phase featuring hyaline membranes (arrow) and alveolar walls congested with infiltrating mononuclear cells and associated cellular debris and minimal alveolar haemorrhage (HE x100). (B) DAD organising phase featuring proliferating myofibroblasts (asterix) within the alveolar duct airspace along with substantial alveolar damage (HE x100). (C) Acute bronchopneumonia featuring prominent intra-alveolar neutrophilic inflammation (HE x100). (D) Pulmonary oedema, consistent with probable acute cardiac failure, characterised by a diffuse distribution of eosinophilic

intra-alveolar space transudate along with alveolar capillary congestion and focal intra-alveolar haemorrhage (HE x200).




Figure 2: Haematoxylin and eosin-stained post-mortem lung sections – thrombotic phenomena in lung tissue

(A) Fibrin-rich pulmonary thrombo-embolism in medium-sized pre-acinar pulmonary artery, characterised by bright eosinophilic layered morphology, with surrounding lung parenchyma featuring exudative DAD (HE x40). (B) Fibrin-rich pulmonary thrombi in intra-acinar pulmonary artery (HE x200). (C) Platelet-rich microthrombus causing dilatation of the vessel, with surrounding features of exudative DAD (HE x200). (D) Platelet-rich microthrombus causing expansion of small-sized intra-acinar pulmonary vessel (HE x400).

There was a degree of overlap among these patterns of disease with 10/46 (21.7%) revealing a secondary pathology (Figure 3). The most common pathologies to overlap were DAD and BRON, seen in 4/46 (8.7%).




Figure 3. Pathological pulmonary phenotypes. Each circle represents total cases where this phenotype was predominant. Shared space between circles indicates all instances of overlap between pathology groups. In these cases, the primary pathology in each case is labelled as ‘1°’ following dotted lines.

Figure created in R.

Two other pathological features observed were microthrombi which featured in 15/46 cases (32.6%, Figure 2), and alveolar/perivascular lymphohistiocytic infiltrates in 9/46 cases (19.6%). The microthrombi in small vessels were predominantly platelet-rich and occurred in the context of DAD in 12/15 cases, but also occurred in two cases of BRON and in one case of PO-PACF. The lymphohistiocytic infiltrates were also seen chiefly in DAD in 6/9 cases but also in two cases of PTE and one case of BRON.

3.3 DAD: the major pathological phenotype in community-based COVID-19 PMLT

DAD was the dominant pathology in 26/46 (56.5%) cases. 25/26 (96.2%) were in the exudative phase of DAD and 1/26 (3.8%) was in the organising phase. Microscopic lesions ranged from incipient and patchy to more developed and widespread. The DAD group consisted of twelve females and fourteen males. Respiratory symptoms were only explicitly reported prior to death on the post-mortem report for 11/26 (42.3%) of these cases.

Cases with DAD as the primary pathology were significantly younger than those with other phenotypes (57.6 years v. 70.6 years, $p=0.02$, Figure 4A). Duration of illness ranged from 0-21 days (median 4.5 days) and was not significantly different to those with other phenotypes where the range was 0-23 (median 7 days) ($p=0.6$, Figure 4B). The DAD group had a comparable co-morbidity burden to those with other dominant phenotypes. Of note, DAD cases had a significantly higher BMI than those with other phenotypes (35.7kg/m^2 v. 24.35kg/m^2 , $p=0.0002$, Figure 4C). Compared to other pathologies, cases with DAD had significantly greater average heart weight (468g v. 403g, $p=0.0439$, Figure 4D), right lung weight (986g v. 740g, $p=0.002$, Figure 4E) and left lung weight (830g v. 649g, $p=0.0079$, Figure 4F).




Figure 4. Comparative statistical analyses comparing DAD group with others with another dominant phenotype in (A) Age at death, (B) Duration of Illness, (C) BMI, (D) Heart Weight, (E) Right Lung Weight and (F) Left Lung Weight.

3.4 Other pathological phenotypes featuring in community-based COVID-19 PMLT

Bronchopneumonia was the dominant pathology phenotype in 11/46 cases (23.9%). Five in this group were men, six were women. Respiratory symptoms were reported prior to death for 6/11 (54.5%) of cases. There were seven cases of PO-PACF, of whom two were female and five were male. Age ranged from 31-87 (median=79). Illness duration ranged from 3-10 days (average 7.2 days),

indicating periods where symptomatic COVID-19 disease proceeded what appeared to be rapid deteriorations. Of interest, in two of these cases, microthrombi were present in small vessels within the myocardium but not in the lung parenchyma.

Pulmonary thromboembolism in medium and large calibre arteries was seen as the dominant histology in 2/46 cases (4.3%). One was a 19-year-old female, the other an 87-year-old female. Pulmonary thromboembolism appeared as a secondary pathology in two cases, with DAD as the primary.

3.5 Cardiac Findings

Median heart weight was 427g (range 230-700g). The heart was described as “normal” in 13/46 cases. In 14 cases, the heart was described as hypertrophic and in 12/14 the heart weight was over 500g. The expected normal heart weights are 365 ± 71 g in men and 312 ± 78 g in women¹⁹. Ventricular dilatation was reported in seven cases. Severe coronary artery atheromatosis was reported in ten cases, one of these had severe triple vessel atheromatosis, all others had involvement of one vessel including one case with critical stenosis. One heart showed a left ventricular posterior scar consistent with old acute myocardial infarction and another revealed acute myocardial infarction in the anterior ventricular wall.

A median of 3 (range: 0-6,) full-thickness ventricular cardiac tissue blocks/case were examined. In one case of primary bronchopneumonia, cardiac microscopy revealed an acute infarction less than 48 old (Figure 5A-B). Thrombi in the heart were found in four cases. In one case, the thrombus was attached to the atrial side of the mitral valve and was predominantly composed of fibrin, with focal platelet-rich areas. The remaining three cases revealed microthrombi within small vessels (Figure 5C-D).

Two cases revealed sparse lympho-histiocytic inflammatory foci without associated myocyte damage, but no cases with significant lymphocytic inflammatory infiltrates were seen.

The lung pathology phenotypes associated with cardiac pathologies are summarised in Supplemental Table 1. Notably, four cases of lung PO-PACF were associated with severe atheroma/thrombi and cardiomegaly (heart >500g), while a fifth case appeared to be related to cocaine consumption.




Figure 5: Haematoxylin and eosin-stained post-mortem heart sections

(A) Epicardial coronary artery blocked with thrombus formation (arrow), with associated recent (<48 hours) acute myocardial infarction characterised by eosinophilic anucleated myocytes (asterix) (HE x40). (B) Same coronary arterial thrombus (asterix) at higher magnification, featuring its significantly *platelet-rich* composition (HE x200). (C) An intramyocardial coronary vessel (likely a vein) dilated due to a *platelet-rich* microthrombus, characterised by pale eosinophilic punctiform loose appearances (HE x100). (D) *Fibrin-rich* non-occlusive thrombus (arrow) attached to a small intramyocardial coronary artery wall, characterised by bright dark eosinophilic dense morphology and lack of platelet definition (HE x400).

3.6 Low symptom burden commonly features in those who died at home with COVID-19

20/46 (43.5%) died with severe COVID-19-related lung disease with collateral evidence of a low symptom burden as defined above. Interestingly, 15/20 (75%) of the low symptom burden cluster were in the DAD group. Psychosocial reasons for not presenting to hospital were cited in five cases. 4/5 of these cases had significant symptoms and would not have been considered to be in the 'low symptom burden group'. In two of these scenarios, first-responder emergency assistance was called for symptomatic COVID-19, however the individual died prior to ambulance arrival. In another two cases, ambulances were called by families due to concerns regarding symptomatic COVID-19 however on arrival the affected individual 'declined going to hospital'. In one instance, an individual sought advice from an urgent care service to be told their symptoms were too mild for hospital assessment. This patient was not included in the 'low symptom burden' group as the qualifier 'mild' was from the perspective of the urgent care service operative rather than the individual themselves or their family.

4. Discussion

This autopsy series offers unique insights into the natural history of COVID-19 in the absence of major pharmacological and medical interventions. Here we have described the clinical data, macroscopic findings and histopathology of a relatively young cohort of significant size compared to preceding series⁸⁻¹⁴ who died of the direct consequence of COVID-19 at home. Our key finding was that DAD was the most common pathological phenotype in community-based deaths, featuring in 56.5% of the cohort, consistent with similar case series⁸⁻¹⁴. The majority of the cohort were in the exudative phase of DAD with only one having progressed to a predominantly organising phase. This is in stark contrast to hospital-based series where the organising phase of DAD is more dominant. Although using different nomenclature, Li *et al.* (2021) noted 7/30 (23%) of their cohort to be ‘organising predominant’ and 12/30 (40%) to be ‘fibrosing predominant’²⁰. DAD in the community setting is an extremely unusual phenomenon²¹. DAD is the most common histological pattern in ARDS¹⁵ and is usually associated with significant symptom burden, hospitalisation and intensive care requirements¹⁵. Katzenstein, one of the pathologists who originally described DAD³, warned colleagues of caution when diagnosing DAD in patients not receiving mechanical ventilation¹⁶. This rule of thumb was applicable to community-based post-mortem series prior to 2020, however the COVID-19 pandemic appears to have created a significant paradigm shift. COVID-19-associated DAD appears morphologically indistinct to DAD caused by other pathologies in histopathological analysis²², however subtle differences such as significantly increased pulmonary capillary microthrombi when compared to influenza DAD have been observed²³.

Hospital-based autopsy series have demonstrated significant heterogeneity of injury patterns in COVID-19 PMLT. Superimposed bronchopneumonia is common and can be bacterial⁵ or fungal²⁴ in aetiology. Some patients have little to no lung involvement, with 11/40 (27.5%) in one series having no specific acute lung injury features, typically dying of cardiac arrest and displaying pulmonary vascular congestion⁶. There is also a high incidence of pulmonary thromboembolism²⁵. This heterogeneity has not, until now, been sufficiently reflected in community-based series. Whilst DAD was our most common dominant pathology, this often ‘overlapped’ with acute bronchopneumonia, acute cardiac failure and pulmonary thromboembolism. In other cases, these represented the dominant pathological picture.

Bronchopneumonia was the second most common dominant pathology pattern. Viral pneumonias such as influenza are well understood to predispose individuals to secondary bacterial infection through a range of mechanisms including architectural disruption and immune response alterations²⁶. This also seems to be the case in COVID-19⁵ although the precise mechanisms underlying this emerging association require exploration.

Similarly, we documented seven cases with evidence of deterioration by acute cardiac failure. The pulmonary oedema seen in such cases represents a diagnostic challenge because it is itself an early feature of exudative DAD³. Therefore, to be confident enough that pulmonary oedema was likely associated with acute cardiac failure, we combined cardiopulmonary macroscopic features and cardiac histology with an absence of hyaline membranes or alveolar damage in lung histology. This attempt to identify PO-PACF cases was deliberate since it is well known that COVID-19 infection might precipitate acute cardiac failure alone through hypoxic respiratory failure, cytokine and catecholamine dysregulation and unmasking of pre-existing cardiac conditions such as critical coronary occlusion and plaque destabilisation⁵.

Consequently, it is important to consider lung findings alongside cardiac findings given the insults generated by SARS-CoV-2 on the entire cardiopulmonary unit. One large series of 2736 hospitalised COVID-19 patients found that myocardial injury was common (36%) but usually mild, and more

frequent in patients with previous cardiovascular diseases²⁷. In our cohort, 72% of the cases were considered to harbour a significant cardiac pathological abnormality, such as cardiomegaly, severe coronary artery atheromatosis, old and acute myocardial infarction and/or microthrombosis. Hence, because of this pathoclinical correlation, 15% of our cases were considered to have died of acute cardiac failure. Of interest, epicardial coronary arterial disease appears to be a risk factor, and cardiac failure may also be precipitated by cytokine storms, microthrombosis, myocarditis and hypoxaemia, perhaps in combination, leading to metabolic supply/demand mismatch²⁸. Notably, Pellegrini *et al.* (2021) differentiated between acute myocardial infarction (defined as area of necrosis $\geq 1\text{cm}^2$) and focal myocyte necrosis ($<1\text{cm}^2$), with the latter being more common (11/14 cases) than the former (3/14 cases). Direct immune-mediated myocardial damage has been preliminarily investigated as well with Basso *et al.* (2020) noting that only 3/21 (14%) hearts had lymphocytic myocarditis and 18/21 (86%) had increased interstitial macrophage infiltration by immunostaining²⁹, an element that was not investigated in our cohort.

The association between severe COVID-19, coagulopathy and thrombosis is an area of urgent pathophysiological investigation³⁰. Pulmonary microthrombi were common in our cohort (15/46 cases) and PTE was the primary pathology in two cases. COVID-19 is certainly also a systemic vascular disease given the significant endothelial dysfunction and endothelitis^{23,31}, changes in platelet distribution and behaviour³² and systemic coagulopathy that has been found^{33,34}. We can ascribe PTE as a direct cause of death in two patients and also as a concomitant severe phenomenon in two other patients who had DAD as their predominant pathology. Although the endothelial damage associated with SARS-CoV-2 may be one precipitant to thrombus formation, SARS-CoV-2 may cause coagulopathy through a variety of mechanisms including direct platelet infection, activation and aggregation³⁵.

Platelet-fibrin microthrombi are a common feature of COVID-19 autopsy series, present in 33/38 (87%) in one series⁴. Thrombi are described as ‘white thrombi’, which are predominantly platelet-rich and ‘red thrombi’ which are predominantly fibrin-rich³⁶. In our cohort, the small vessel microthrombi in the lungs were also predominantly platelet-rich, in agreement with findings from Rapkiewicz *et al.* (2020)³². Conversely, Pellegrini *et al.* (2021) noted that cardiac microthrombi in COVID cases were significantly richer in fibrin when compared to their control non-COVID counterparts³⁷. Microthrombi occurred in the context of DAD in 12 cases, but also in two cases with bronchopneumonia and one case of acute cardiac failure without DAD, indicating these microthrombi may not be directly related with COVID-19 pneumonitis but with COVID-19-associated coagulopathy.

Classically, thrombi seen in the setting of non-COVID-related DAD tend to be ‘fibrin-rich’¹⁶. Extensive platelet-rich microthrombi used to be a rarity, with only a few cases reported in post-liver and lung transplant pathology^{38,39}. Therefore, platelet-rich microthrombi may also be particular to COVID-19. Indeed, Nishikawa *et al.* (2021) showed excessive platelet aggregates in 90% of COVID-19 patients, these being linked with disease severity, mortality, severity of respiratory condition and vascular endothelial dysfunction⁴⁰. Interestingly, there were cases in this cohort with low D-dimers (cross-linked fibrin monomers), indicating platelet aggregation with relative absence of significant fibrin activity. Platelets express ACE2 and TMPRESS2, can be functionally hyperactive when isolated from COVID-19 patients and, in *in vitro* and murine models, SARS-CoV-2 and spike protein has been shown to bind to platelets and enhance activation activities including aggregation and the release of coagulation and inflammatory factors³⁵.

By comparing DAD case demographics to all other dominant pathological lung phenotypes in our cohort, we found some notable differences including a younger age profile and obesity. Obese patients may be more likely to contract SARS-CoV-2, are more likely to have concurrent comorbidities, have reduced capacity to mount innate and adaptive immune responses including to

vaccination and have increased morbidity and mortality in COVID-19⁴¹. Obesity was the most common comorbidity in our cohort and we suspect that reduced respiratory reserve may have contributed to more rapid progression of pre-hospital deaths.

We hypothesised that a low symptom burden may have led to a failure of hospital presentation and found it to be a frequently represented narrative in community-based COVID-19 deaths. The low symptom group were asymptomatic or had mild or absent lower respiratory tract symptoms, yet clearly died with pathological features of significant COVID-19 lung disease. The majority of this group (15/20, 75%) had DAD as their predominant lung pathology. To our knowledge, this is the first attempt at estimating the symptomatic burden of COVID-19 sufferers prior to death in the community setting. We suspect that this low symptom burden might be at least partially explained by the phenomenon of 'silent hypoxaemia', whereby COVID-19-affected individuals might display pronounced arterial hypoxaemia due to severe lung pathology in the relative absence of dyspnoea⁴². Prevalence is estimated at 20-40%¹⁷ with several possible underlying mechanisms postulated including direct viral effects on ACE2-expressing peripheral chemoreceptors⁴³, nasal mucosa⁴⁴ and central respiratory centres⁴⁵ as well as indirect modulatory effects via immune-mediated inflammatory mediators⁴⁶. Relatively preserved carbon dioxide clearance may mask symptoms given respiratory centre sensitivity to hypercapnoea rather than hypoxaemia⁴⁷. Blunting of respiratory centres with age and diabetes⁴⁷ may contribute but does not offer an explanation in our cohort which was relatively young with a low prevalence of diabetes (8/47, 17%). Compared to 'typical' ARDS, COVID-19 lungs demonstrate relatively preserved compliance⁴⁸ suggesting potential for preserved signalling via juxtacapillary J stretch mechanoreceptors⁴². Early exudative DAD, especially if incipient, as well as microthrombosis may underlie a large ventilation-perfusion mismatch but confer relatively preserved lung mechanics compared to congested, organising and fibrotic lungs associated with late DAD and bronchopneumonia. This would fit with our cohort where 96.2% of DAD cases were considered predominantly exudative DAD. Compliance is intricately linked with surfactant production and it has been hypothesised that early preservation of its production may partly underlie silent hypoxaemia⁴⁹. However, surfactant-producing Type II pneumocytes are the principle ACE2-expressing cells in the lungs⁵⁰, become virally infected⁴ and do downregulate surfactant genes⁵¹.

Other reasons cited which may have precluded hospital admission included psychosocial factors and healthcare resource factors. Fear of visiting hospital during the pandemic has been widely reported with deaths attributable to delayed presentation due to fear⁵². We can speculate that fear, stoicism and reluctance to further burden an overstretched healthcare system may have contributed. Concerningly, one individual sought advice from a medical advice service and was told they did not have enough symptoms for hospital assessment. Knowing that severe histological disease and a low symptom burden can co-exist, clinicians may consider a lower threshold for face-to-face assessment in the future.

5. Limitations

Autopsy series are fundamentally limited in that they only reflect the final frame of disease progression. The clinical data obtained for this study was limited by the information provided from collateral history provided by next of kin and recorded in post-mortem reports. Reporting of macroscopic features and tissue sampling performed by pathologists with differing degrees of expertise in cardiopulmonary pathology. Sampling of organs for histological evaluation was not uniform across all cases, although we felt our high lung tissue block average was sufficient to draw robust conclusions in all cases. Our cardiac tissue block sampling was lower yet was still useful to understand the cardiac pathology in some cases but not universally. These limitations were mitigated with all clinical data and microscopic data reviewed by a consultant histopathologist with cardiothoracic expertise. Although all the autopsies fulfilling the inclusion criteria were included, the cohort reported in this study may have a selection bias towards unexpected and unexplained deaths and as a result younger people with low reported symptom burden would be more likely to be selected for HM Coroner autopsy. We did not collect information pertaining to the socioeconomic circumstances of individuals, but given the NHS has universal free at the point of care coverage we suspect socioeconomic disadvantage plays a more limited role than it might in some other countries.

6. Conclusion

This study reveals that heterogeneous, overlapping and severe COVID-19 lung disease pathologies occur in the pre-hospital community-based setting. Published autopsy series are the virtual sepulchres of the COVID-19 era and their clinical narratives the 'epitaphs' providing the context required to appropriately interpret tissue findings. DAD commonly featuring in community autopsies represents a paradigm shift of this era and one explanation might include unsensed hypoxaemia, a clinical phenomenon which should be put under the microscope.

Author Contributions: Conceptualisation - L.M., J.M. & A.Fis.; Figure and table development – L.M., J.M., B.H.; Writing – original draft – L.M.; Writing – review and editing – J.M., J.P., S.H., N.C., B.H., C.J.A.D., A.Fil. & A.Fis.

Funding: A.Fis., A.Fil. and C.J.A.D are partly funded by UKRI/Medical Research Council through the UK Coronavirus Immunology Consortium (UK-CIC). This funding supported work generating the figures provided and otherwise played no role in the production of this manuscript. L.M. is funded by a General Sir John Monash Scholarship awarded by the General Sir John Monash Foundation and a Vice-Chancellor’s Global Scholarship from Newcastle University in support of a Master of Research in Immunobiology at Newcastle University. C.J.A.D. is funded by a Wellcome Clinical Research Career Development Fellowship (211153/Z/18/Z).

Conflicts of Interest: The authors declare no conflict of interest.

Acknowledgements: The authors would like to acknowledge the significant and ongoing research activities being conducted by all members of ‘Theme 3: Immunopathology’: UK Research and Innovation Coronavirus Immunology Consortium. The authors would like to acknowledge Iqbal Bhalla for the creation of Figure 3. The authors would finally like to acknowledge the tissue donors and their families for their contribution to medical science.

Ethics Approval: This project is covered by Newcastle Hospitals CEPA Biobank ethics – REC 17/NE/0070.

References

1. Costache M, Lazaroiu AM, Contolenco A, Costache D, George S, Sajin M, et al. Clinical or postmortem? The importance of the autopsy; a retrospective study. *Maedica (Bucur)*. 2014;9(3):261-5.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.
3. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage--the role of oxygen, shock, and related factors. A review. *Am J Pathol*. 1976;85(1):209-28.
4. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *The Lancet Infectious Diseases*. 2020;20(10):1135-40.
5. Grosse C, Grosse A, Salzer HJF, Dünser MW, Motz R, Langer R. Analysis of cardiopulmonary findings in COVID-19 fatalities: High incidence of pulmonary artery thrombi and acute suppurative bronchopneumonia. *Cardiovasc Pathol*. 2020;49:107263.
6. De Michele S, Sun Y, Yilmaz MM, Katsyv I, Salvatore M, Dzierba AL, et al. Forty Postmortem Examinations in COVID-19 Patients. *Am J Clin Pathol*. 2020;154(6):748-60.
7. Milross L, Majo J, Cooper N, Kaye PM, Bayraktar O, Filby A, et al. Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19. *The Lancet Respiratory Medicine*. 2021.
8. Youd E, Moore L. COVID-19 autopsy in people who died in community settings: the first series. *Journal of Clinical Pathology*. 2020;73(12):840.
9. Suess C, Hausmann R. Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation. *Int J Legal Med*. 2020;134(4):1285-90.
10. Ducloyer M, Gaborit B, Toquet C, Castain L, Bal A, Arrigoni PP, et al. Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations. *Int J Legal Med*. 2020;134(6):2209-14.
11. Aguiar D, Lobrinus JA, Schibler M, Fracasso T, Lardi C. Inside the lungs of COVID-19 disease. *International journal of legal medicine*. 2020;134(4):1271-4.
12. Williams AS, Dmetrichuk JM, Kim P, Pollanen MS. Postmortem radiologic and pathologic findings in COVID-19: The Toronto experience with pre-hospitalization deaths in the community. *Forensic Science International*. 2021;322:110755.
13. Oprinca GC, Muja LA. Postmortem examination of three SARS-CoV-2-positive autopsies including histopathologic and immunohistochemical analysis. *Int J Legal Med*. 2021;135(1):329-39.
14. Tombolini A, Scendoni R. SARS-CoV-2-related deaths in routine forensic autopsy practice: histopathological patterns. *International journal of legal medicine*. 2020;134(6):2205-8.
15. Parambil JG, Myers JL, Aubry MC, Ryu JH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. *Chest*. 2007;132(1):50-7.
16. Katzenstein AL. *Diagnostic Atlas of Non-Neoplastic Lung Disease: A Practical Guide for Surgical Pathologists* 2016: pp. 125.
17. Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MA, Hosen MJ. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. *Mol Biol Rep*. 2021;48(4):3863-9.
18. Hanley B, Lucas SB, Youd E, Swift B, Osborn M. Autopsy in suspected COVID-19 cases. *Journal of Clinical Pathology*. 2020;73(5):239.
19. de la Grandmaison GL, Clairand I, Durigon M. Organ weight in 684 adult autopsies: new tables for a Caucasoid population. *Forensic Science International*. 2001;119(2):149-54.

20. Li Y, Wu J, Wang S, Li X, Zhou J, Huang B, et al. Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID-19 pneumonia in Wuhan, China. *Histopathology*. 2021;78(4):542-55.
21. Nur Urer H, Ersoy G, Yilmazbayhan ED. Diffuse alveolar damage of the lungs in forensic autopsies: assessment of histopathological stages and causes of death. *ScientificWorldJournal*. 2012;2012:657316.
22. Konopka KE, Nguyen T, Jentzen JM, Rayes O, Schmidt CJ, Wilson AM, et al. Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DAD. *Histopathology*. 2020;77(4):570-8.
23. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *New England Journal of Medicine*. 2020;383(2):120-8.
24. Evert K, Dienemann T, Brochhausen C, Lunz D, Lubnow M, Ritzka M, et al. Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation. *Virchows Archiv*. 2021.
25. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. *Ann Intern Med*. 2020;173(4):268-77.
26. Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. *Frontiers in microbiology*. 2017;8:1041-.
27. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. *J Am Coll Cardiol*. 2020;76(5):533-46.
28. Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, et al. Cardiovascular manifestations and treatment considerations in COVID-19. *Heart*. 2020;106(15):1132-41.
29. Basso C, Leone O, Rizzo S, De Gaspari M, van der Wal AC, Aubry M-C, et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. *European Heart Journal*. 2020;41(39):3827-35.
30. Dwiputra Hernugrahanto K, Novembri Utomo D, Hariman H, Budhiparama NC, Medika Hertanto D, Santoso D, et al. Thromboembolic involvement and its possible pathogenesis in COVID-19 mortality: lesson from post-mortem reports. *Eur Rev Med Pharmacol Sci*. 2021;25(3):1670-9.
31. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet*. 2020;395(10234):1417-8.
32. Rapkiewicz AV, Mai X, Carsons SE, Pittaluga S, Kleiner DE, Berger JS, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. *eClinicalMedicine*. 2020;24.
33. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. *J Thromb Thrombolysis*. 2020;50(1):54-67.
34. Acanfora D, Acanfora C, Ciccone MM, Scicchitano P, Bortone AS, Uguccioni M, et al. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. *Viruses*. 2021;13(10).
35. Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *Journal of Hematology & Oncology*. 2020;13(1):120.
36. Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. *Anesth Analg*. 2012;114(2):275-85.
37. Pellegrini D, Kawakami R, Guagliumi G, Sakamoto A, Kawai K, Gianatti A, et al. Microthrombi as a Major Cause of Cardiac Injury in COVID-19. *Circulation*. 2021;143(10):1031-42.
38. Sankey EA, Crow J, Mallett SV, Alcock RJ, More L, Burroughs AK, et al. Pulmonary platelet aggregates: possible cause of sudden peroperative death in adults undergoing liver transplantation. *J Clin Pathol*. 1993;46(3):222-7.

39. Bravo C, Majó J, Ruiz F, Muntaner L, Monforte V, Solé J, et al. Platelet thromboembolism after lung transplantation. *J Transplant*. 2009;2009:650703.
40. Nishikawa M, Kanno H, Zhou Y, Xiao T-H, Suzuki T, Ibayashi Y, et al. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. *Nature Communications*. 2021;12(1):7135.
41. Albashir AAD. The potential impacts of obesity on COVID-19. *Clin Med (Lond)*. 2020;20(4):e109-e13.
42. Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of 'happy' hypoxemia in COVID-19. *Respiratory Research*. 2020;21(1):198.
43. Fung ML. Expressions of angiotensin and cytokine receptors in the paracrine signaling of the carotid body in hypoxia and sleep apnea. *Respir Physiol Neurobiol*. 2015;209:6-12.
44. Rittayamai N, Tscheikuna J, Praphruetkit N, Kijpinyochai S. Use of High-Flow Nasal Cannula for Acute Dyspnea and Hypoxemia in the Emergency Department. *Respiratory Care*. 2015;60(10):1377.
45. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and Renal Tropism of SARS-CoV-2. *The New England journal of medicine*. 2020;383(6):590-2.
46. Hsieh YH, Litvin DG, Zaylor AR, Nethery DE, Dick TE, Jacono FJ. Brainstem inflammation modulates the ventilatory pattern and its variability after acute lung injury in rodents. *J Physiol*. 2020;598(13):2791-811.
47. Tobin MJ, Laghi F, Jubran A. Why COVID-19 Silent Hypoxemia Is Baffling to Physicians. *American journal of respiratory and critical care medicine*. 2020;202(3):356-60.
48. Li X, Ma X. Acute respiratory failure in COVID-19: is it "typical" ARDS? *Critical Care*. 2020;24(1):198.
49. Chandra A, Chakraborty U, Pal J, Karmakar P. Silent hypoxia: a frequently overlooked clinical entity in patients with COVID-19. *BMJ Case Reports*. 2020;13(9):e237207.
50. Salamanna F, Maglio M, Landini MP, Fini M. Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. *Frontiers in Medicine*. 2020;7.
51. Delorey TM, Ziegler CGK, Heimberg G, Normand R, Yang Y, Segerstolpe Å, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. *Nature*. 2021.
52. Bansal S, Roy M, Chatterjee T, Roy AK. Deaths due to delayed presentation to the hospital from fear of contracting COVID-19 during lockdown period: a tertiary care center experience. *Journal of Community Hospital Internal Medicine Perspectives*. 2021;11(3):299-301.

4. Supplementary Materials

Supplemental Table 1. Primary cardiac pathologies in the cohort and cases of overlap with primary lung pathologies and concurrent cardiac pathologies.

Cardiac Pathology	n	Associated Primary Lung Phenotypes				Overlapping Cardiac Pathology
		DAD	BRON	PO-PACF	PE	
Normal Heart	13	7	3	2	1	
Hypertrophic/ cardiomegalic (>500g)	12	9	1	2	0	Severe atheroma (2), aortic stenosis (1)
Severe atheromatosis	10	4	3	3	0	Thrombi (3), cardiomegalic (2)
Aortic stenosis	2	1	1	0	0	Cardiomegalic (1)
Amyloidosis	2	1	1	0	0	
Cardiac Thrombi	4	1	1	2	0	Severe atheroma (3)